• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分期:肺癌合理管理的关键

Staging: the key to rational management of lung cancer.

作者信息

Miller J D, Gorenstein L A, Patterson G A

机构信息

Department of Surgery, Toronto Hospital, Ontario, Canada.

出版信息

Ann Thorac Surg. 1992 Jan;53(1):170-8.

PMID:1728232
Abstract

Staging is the quantitative assessment of malignant disease and allows logical groupings of patients with a similar extent of disease for prognostic, therapeutic, and analytic purposes. In bronchogenic carcinoma a stage is assigned based on size, location, and the extent of invasion of the primary tumor, as well as the presence of any regional or metastatic disease. Selecting the most appropriate treatment for a patient with bronchogenic carcinoma depends on precise staging. The extent of local invasion and presence of metastatic disease will determine the likelihood of complete resection and possible cure. Careful assessment of the history, blood chemistry, radiographic studies, bronchoscopy, mediastinoscopy, and exploration (thoracotomy) are all important staging tools. Routine radionuclide scans have no useful role when there is no clinical or laboratory evidence of metastases. The T status of a tumor is best judged by bronchoscopy and at thoracotomy. Thoracic surgeons must be familiar with the techniques available to determine T status intraoperatively and use this information when planning resection. Computed tomography of the chest has fallen short in predicting direct invasion of the mediastinum and chest wall. Cervical and anterior mediastinoscopy remain important tools in determining operability. Intraoperative assessment of node involvement determines the extent of resection and likelihood of cure.

摘要

分期是对恶性疾病的定量评估,它能根据疾病程度对患者进行合理分组,以用于预后、治疗及分析目的。在支气管源性肺癌中,分期是基于原发肿瘤的大小、位置、浸润范围以及是否存在任何区域或转移性疾病来确定的。为支气管源性肺癌患者选择最合适的治疗方法取决于精确的分期。局部浸润范围和转移性疾病的存在将决定能否完全切除以及治愈的可能性。仔细评估病史、血液化学指标、影像学检查、支气管镜检查、纵隔镜检查和探查(开胸手术)都是重要的分期手段。当没有临床或实验室证据表明存在转移时,常规放射性核素扫描没有实际作用。肿瘤的T分期最好通过支气管镜检查和开胸手术来判断。胸外科医生必须熟悉术中确定T分期的可用技术,并在规划切除手术时利用这些信息。胸部计算机断层扫描在预测纵隔和胸壁的直接浸润方面存在不足。颈部和前纵隔镜检查仍然是确定可手术性的重要手段。术中对淋巴结受累情况的评估决定了切除范围和治愈的可能性。

相似文献

1
Staging: the key to rational management of lung cancer.分期:肺癌合理管理的关键
Ann Thorac Surg. 1992 Jan;53(1):170-8.
2
Surgical exploration of the mediastinum: mediastinoscopy and intraoperative staging.纵隔的外科探查:纵隔镜检查与术中分期
Lung Cancer. 2004 Aug;45 Suppl 2:S55-61. doi: 10.1016/j.lungcan.2004.07.992.
3
A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma.磁共振成像、计算机断层扫描和纵隔镜检查在支气管源性癌纵隔淋巴结状态术前评估中的前瞻性评价
J Thorac Cardiovasc Surg. 1987 Nov;94(5):679-84.
4
[Multimodal treatment of non small cell lung cancer].[非小细胞肺癌的多模式治疗]
Zentralbl Chir. 2006 Apr;131(2):110-4. doi: 10.1055/s-2006-921534.
5
Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.计算机断层扫描和正电子发射断层扫描筛查的I期肺癌患者常规纵隔镜检查的成本效益
J Thorac Cardiovasc Surg. 2006 Apr;131(4):822-9; discussion 822-9. doi: 10.1016/j.jtcvs.2005.10.045. Epub 2006 Mar 2.
6
Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma of the left lung.扩大颈部纵隔镜检查在左肺支气管源性癌分期中的应用
Eur J Cardiothorac Surg. 2008 Nov;34(5):1081-4. doi: 10.1016/j.ejcts.2008.07.034. Epub 2008 Aug 29.
7
Mediastinal staging of lung cancer: the changing role of mediastinoscopy.肺癌的纵隔分期:纵隔镜检查作用的变化
Isr J Med Sci. 1995 Feb-Mar;31(2-3):122-4.
8
Staging techniques for lung cancer.肺癌的分期技术
Chest Surg Clin N Am. 2000 Nov;10(4):781-801.
9
Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.1期非小细胞肺癌临床分期与病理分期之间的一致性较差:来自前瞻性试验CALGB 9761的结果。
Lung Cancer. 2005 May;48(2):241-6. doi: 10.1016/j.lungcan.2004.11.006. Epub 2005 Jan 4.
10
Computed tomography and mediastinoscopy in the assessment of resectability of lung cancer.
Acta Radiol. 1989 Mar-Apr;30(2):169-73.

引用本文的文献

1
Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.表皮生长因子受体突变型晚期肺癌治疗方式的预后结果。
Korean J Intern Med. 2022 Jul;37(4):811-820. doi: 10.3904/kjim.2021.488. Epub 2022 Jun 3.
2
Inhibiting of Proliferation, Migration, and Invasion in Lung Cancer Induced by Silencing Interferon-Induced Transmembrane Protein 1 (IFITM1).沉默干扰素诱导跨膜蛋白 1(IFITM1)抑制肺癌的增殖、迁移和侵袭。
Biomed Res Int. 2019 May 8;2019:9085435. doi: 10.1155/2019/9085435. eCollection 2019.
3
Suppression of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer cell line.
抑制表皮生长因子受体-信号转导和转录激活因子3信号通路可抑制肺癌细胞系的肿瘤发生。
Int J Clin Exp Med. 2014 Aug 15;7(8):2096-9. eCollection 2014.
4
Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.晚期非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂敏感性的分子预测指标
Int J Med Sci. 2008 Jul 11;5(4):209-17. doi: 10.7150/ijms.5.209.
5
Classification of parietal pleural invasion at adhesion sites with surgical specimens of lung cancer and implications for prognosis.肺癌手术标本粘连部位脏层胸膜侵犯的分类及其对预后的影响
Virchows Arch. 2005 Dec;447(6):984-9. doi: 10.1007/s00428-005-0031-2. Epub 2005 Sep 21.
6
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected].Lunx是检测外周血中非小细胞肺癌的一种优良分子标志物[已修正]。
J Mol Diagn. 2003 Nov;5(4):237-42. doi: 10.1016/s1525-1578(10)60480-1.
7
Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.疑似非小细胞肺癌分期检查的实践、疗效及成本:荷兰两家医院的回顾性研究
Thorax. 2002 Jan;57(1):11-4. doi: 10.1136/thorax.57.1.11.
8
Lung Cancer: A Bronchoscopic Approach.肺癌:支气管镜检查法
Pathol Oncol Res. 1996;2(1-2):11-15. doi: 10.1007/BF02893941.